SUPT20H

Across TCGA pan-cancer cohorts, SUPT20H mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SUPT20H data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SUPT20H mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SUPT20H expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and OV are the cancer types where SUPT20H mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.806	0.424	<.001	79	view →
PDAC	DFS	Tertile	All	0.526	0.321	.013	14	view →
OV	DFS	Median	All	0.938	0.616	.020	8	view →
LSCC	DFS	Median	III,IV	0.851	1.000	.013	4	view →
CCRCC	DFS	Tertile	II,III,IV	0.726	0.951	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SUPT20H–LUAD (DFS)

Open the LUAD breakdown →